Listen as Mark Pegram, MD, interviews Lisa A. Carey, MD, ScM, regarding the latest research on breast cancer tumor biology and its relation to age and race.
Historically, demographic factors, such as age, menopausal status, and race, have guided selection of endocrine therapy or chemotherapy for treatment of breast cancer. However, consideration of these characteristics is increasingly less necessary as more is learned about tumor biology and physiologic factors that predict treatment response.
Lisa A. Carey, MD, ScM, is associate professor of medical oncology at the University of North Carolina, Lineberger Comprehensive Cancer Center, in Chapel Hill, North Carolina; and Mark Pegram, MD, is professor of medicine at the University of Miami, Sylvester Comprehensive Cancer Center, Department of Hematology/Oncology, in Miami, Florida. In this interview, Dr. Carey discusses the benefits of selecting appropriate candidates for chemotherapy and endocrine therapy by considering tumor biology before age- or race-related characteristics in women with breast cancer. Listen to her interview to learn more about:
- The move from age-based selection of chemotherapy and endocrine agents for the treatment of breast cancer toward a more biologically based approach
- Age-related differences in molecular subtypes of breast cancer
- Other age-related biologic differences in breast cancer tumors
- The treatment implications of the presence and quantity of estrogen receptors
- Clinical implications of other receptor subtypes (progesterone receptors, EGFR)
- The effectiveness and safety of chemotherapy in postmenopausal women
- Risks of developing breast cancer among different racial and ethnic groups
- Race-related differences in molecular subtypes and other biologic characteristics of breast cancer
- How disparities in risk factors and access to screening may affect the presentation of breast cancer in certain populations